$100 million series E financing for Alzheimer's firm Alzheon

Alzheon, a clinical-stage biopharma company, has secured $100 million in a series E funding round led by Alerce Medical Technology Partners.

The fresh finance comes after the firm’s $50 million series D round, in 2022, and will support the development of ALZ-801 (valiltramiprosate) for Alzheimer’s disease.

Chief executive Martin Tolar said: “Our ability to raise $150 million over the last two financing rounds in the current climate speaks volumes about the prospects of our innovative science and technology.”